Taken together, these results suggest that the inhibition of CysLT1 can be beneficial for colon cancer patients by shifting signaling from the more oncogenic CysLT1 receptor to the more tumor-suppressing CysLT2 receptor. The gene discussed is CYSLTR1; the disease is colonic neoplasm.